Expression patterns of the immune checkpoint ligand CD276 in urothelial carcinoma von Aicher, Wilhelm K, Korn, M, Reitnauer, L, Maurer, F B, Hennenlotter, J, Black, P C, Todenhofer, T, Bedke, J, Stenzl, A

Volltext

Biology of BCG response in non-muscle invasive bladder cancer - 2021 IBCN Updates Part III von Reike, M.J., Ingersoll, M.A., Müller, D.C., Zuiverloon, T.C.M., Strandgaard, T., Kamat, A.M., Williams, S.B., Seiler, R., Todenhöfer, T., Dyrskjøt, L., Nawroth, R., Goebell, P., Schmitz-Dräger, B., Sfakianos, J.P., Meeks, J., Horowitz, A., Black, P.C.

Volltext

No influence of smoking status on the performance of urine markers for the detection of bladder cancer von Deininger, Susanne, Hennenlotter, J., Rausch, S., Docktor, K., Neumann, E., da Costa, I. A., Bedke, J., Stenzl, A., Todenhöfer, T.

Volltext

Impact of perioperative chemotherapy on survival in patients with advanced primary urethral cancer: results of the international collaboration on primary urethral carcinoma von Gakis, G., Morgan, T.M., Daneshmand, S., Keegan, K.A., Todenhöfer, T., Mischinger, J., Schubert, T., Zaid, H.B., Hrbacek, J., Ali-El-Dein, B., Clayman, R.H., Galland, S., Olugbade, K., Rink, M., Fritsche, H.-M., Burger, M., Chang, S.S., Babjuk, M., Thalmann, G.N., Stenzl, A., Efstathiou, J.A.

Volltext

2535 Clinical outcomes in chemotherapy-naïve metastatic castrationresistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (ABI) stratified by prognosis von Aviles, C.M, Azad, A.A, Todenhöfer, T, Eigl, B.J, Kollmannsberger, C, Murray, N, Chi, K

Volltext

Current concepts and trends in the treatment of bone metastases in patients with advanced prostate cancer von Hegemann, Miriam, Maas, Moritz, Rausch, Steffen, Walz, Simon, Bedke, Jens, Stenzl, Arnulf, Todenhöfer, Tilman

Volltext

Prostate cancer and diabetes mellitus - indications for an association between glucose metabolism and androgen receptor signalling von Todenhöfer, T., Russo, G.I., Morgia, G., Broggi, G., Caltabiano, R., Hennenlotter, J., Kühs, U., Lutz, S.Z., Stenzl, A., Heni, M.

Volltext

Expression of immune checkpoint ligand CD276 (B7-H3) is regulated in urothelial carcinoma on a transcriptional and post-transcriptional level and drops significantly in late stage... von Aicher, W., Maurer, F.B., Reitnauer, L., Korn, M., Maas, M., Hennenlotter, J., Todenhöfer, T., Stenzl, A.

Volltext

Amplification of 7p12 is associated with pathologic non-response to neoadjuvant chemotherapy in muscle-invasive bladder cancer von Pichler, R., Lindner, A.K., Compérat, E., Obrist, P., Schäfer, G., Todenhöfer, T., Horninger, W., Zoran, C., Untergasser, G.

Volltext

Laparoscopic radical nephrectomy with inferior vena cava thrombectomy: highlight of key surgical steps von Sim, A., Todenhöfer, T., Mischinger, J., Fahmy, O., Boettge, J., Rausch, S., Bier, S., Aufderklamm, S., Stenzl, A., Gakis, G., Schwentner, C.

Volltext

Influence of age on false positive rates of urine-based tumor markers von Horstmann, M., Todenhöfer, T., Hennenlotter, J., Aufderklamm, S., Mischinger, J., Kuehs, U., Gakis, G., Stenzl, A., Schwentner, C.

Volltext

Biomarkers in Urachal Cancer and Adenocarcinomas in the Bladder: A Comprehensive Review Supplemented by Own Data von Szarvas, Tibor, Nyirády, Péter, Al-Ahmadie, Hikmat, Behrendt, Mark, Herold, Thomas, Módos, Orsolya, Niedworok, Christian, Krafft, Ulrich, Reis, Henning, Hadaschik, B.

Volltext

791 Notch2-HEY axis promotes tumour growth in bladder cancer through cell cycle progression and de-differentiation von Hayashi, T, Goriki, A, Oo, H.Z, Seiler, R, Todenhofer, T, Jaeger, W, Awrey, S, Altamirano-Dimas, M, Fazli, L, Matsubara, A, Black, P

Volltext

Influence of Body Mass Index, Surgical Approach and Lymphadenectomy on the Development of Symptomatic Lymphoceles after Radical Prostatectomy von Mundhenk, J., Hennenlotter, J., Alloussi, S., Selbherr, D., Martzog, J.C., Todenhöfer, T., Kruck, S., Schwentner, C., Stenzl, A., Schilling, D.

Volltext

Cost effective laparoendoscopic single-site surgery with a reusable platform von Schwentner, C, Todenhöfer, T, Seibold, J, Alloussi, S, Aufderklamm, S, Mischinger, J, Stenzl, A, Gakis, G

Volltext

Efficacy and safety of derazantinib (DZB) in patients with metastatic urothelial carcinoma (mUC) with activating FGFR1/2/3 genetic aberrations (GA): Results from the phase 1b/2 FID... von Necchi, A., Todenhöfer, T., Deville, J-L., Häckl, M., Marszewska, M., Mckernan, P., Saulay, M., Engelhardt, M., De Santis, M.

Volltext

Prognostic impact of the Interleukin-1-Beta / Interleukin-1-Receptor-Antagonist axis in bladder cancer von Vukovic, M., Chamlati, J.M., Hennenlotter, J., Baisch, S., Todenhöfer, T., Lütfrenk, T., Grigoriadou, I., Stenzl, A., Rausch, S.

Volltext

A1178 - Prognostic impact of the Interleukin-1-Beta / Interleukin-1-Receptor-Antagonist axis in bladder cancer von Vukovic, M., Chamlati, J.M., Hennenlotter, J., Baisch, S., Todenhöfer, T., Lütfrenk, T., Grigoriadou, I., Stenzl, A., Rausch, S.

Volltext

A0548 - Efficacy and safety of derazantinib (DZB) in patients with metastatic urothelial carcinoma (mUC) with activating FGFR1/2/3 genetic aberrations (GA): Results from the phase... von Necchi, A., Todenhöfer, T., Deville, J-L., Häckl, M., Marszewska, M., Mckernan, P., Saulay, M., Engelhardt, M., De Santis, M.

Volltext

Clinical Significance of Pre-to-Postoperative Dynamics of Aspartate Transaminase/Alanine Transaminase Ratio in Predicting the Prognosis of Renal Cell Carcinoma after Surgical Treat... von Seo, Seong Il, Jeon, Seong Soo, Jeong, Byong Chang, Jeon, Hwang Gyun, Sung, Hyun Hwan, Shin, Seung Jea, Kang, Minyong, Lee, Hyun Moo

Volltext